CLSI-Guided Susceptibility Testing for Nontuberculous Mycobacteria: Methods and Emerging Agents
This review covers CLSI recommendations for first- and second-line drug testing of nontuberculous mycobacteria, including organism-specific methodologies and reporting standards. It also addresses molecular sequencing approaches for detecting resistance to clarithromycin and amikacin, and reviews newer antimicrobials proposed for NTM treatment not yet included in CLSI guidelines.
The original study
Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.
- Authors
- Brown-Elliott BA, Woods GL
- Journal
- Journal of clinical microbiology
- Type
- Journal Article, Review
- PMID
- 31315954
Original abstract
Recommendations for first-line and second-line drug testing and organism group, specific methodologies, and reporting recommendations have been addressed by the Clinical and Laboratory Standards Institute (CLSI) and are important in the selection of appropriate antimicrobial treatment regimens for nontuberculous mycobacteria (NTM) disease. This review also includes recent information on new antimicrobials proposed for the treatment of NTM but not yet addressed by the CLSI and molecular (gene sequencing) methods associated with the detection of antimicrobial resistance of two major therapeutic antimicrobials, clarithromycin and amikacin.